Insulin glargine


Concise Prescribing Info
Indications/Uses
DM.
Dosage/Direction for Use
Adult : SC For insulin-naive patients: May initiate w/ 10 IU once daily, adjust subsequently based on glycaemic response. Usual range: 2-100 IU/day.
Dosage Details
Subcutaneous
Diabetes mellitus
Adult: According to requirements; administer once daily at the same time each day. For insulin-naive patients: May initiate with 10 IU once daily. Adjust subsequently based on response to achieve glycaemic targets. Usual range: 2-100 IU/day.
Child: ≥6 yr: According to requirements; administer once daily at the same time each day.
Renal Impairment
Decreased dose may be necessary.
Hepatic Impairment
Decreased dose may be necessary.
Contraindications
Hypoglycaemia; IV route.
Special Precautions
Renal or hepatic impairment; pregnancy; lactation; child <6 yrs. Transferring from other insulin. Monitor serum glucose, potassium, electrolytes, HbA1c and lipid profile. Concomitant illness esp infections; hypokalaemia.
Adverse Reactions
Hypoglycaemia; oedema; pruritus; rash; hypersensitivity reactions; lipoatrophy or lipohypertrophy with SC Inj (rotate Inj site).
Drug Interactions
Effects may be increased by: oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog (e.g. octreotide), sulfonamide antibiotics. Effects may be decreased by: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents, isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, oral contraceptives, lithium. Signs of hypoglycaemia may be masked by β-blockers, clonidine.
Action
Description: Insulin glargine, a long-acting analog of human insulin, regulates carbohydrate, protein and fat metabolism by inhibiting hepatic glucose production and lipolysis, and enhancing peripheral glucose disposal.
Onset: 1 hr
Duration: 24 hrs.
Disclaimer: This information is independently developed by MIMS based on Insulin glargine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in